AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.
about
Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B.Automated discovery of novel drug formulations using predictive iterated high throughput experimentationAmphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney functionAmphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney functionDrugs for treating paracoccidioidomycosisPharmacological interventions for paracoccidioidomycosisCurrent challenges in treatment options for visceral leishmaniasis in India: a public health perspectiveEfficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparisonToxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Treatment of visceral leishmaniasis.Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsApplication of caspofungin in China compared with amphotericin B and fluconazole.Nanomedicine--challenge and perspectives.Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy.Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.Structures, targets and recent approaches in anti-leishmanial drug discovery and development.Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic.Liposomal amphotericin B: clinical experience and perspectives.Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy.Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Optimizing efficacy of amphotericin B through nanomodification.A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants.In vitro and in vivo study on the effect of antifungal agents on hematopoietic cells in mice.Optimizing efficacy of Amphotericin B through nanomodification.Nanocarriers' entry into the cell: relevance to drug delivery.The Mechanistic Targets of Antifungal Agents: An Overview.Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives.Nanoparticle-mediated pulmonary drug delivery: a reviewNanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity.Direct transbronchial administration of liposomal amphotericin B into a pulmonary aspergilloma.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.
P2860
Q21146447-AB8AAF4F-522C-41E5-97F8-BED00E1BD319Q21562603-64CDD262-29DC-427A-BD92-47802DC1C67BQ24187699-80B2DCC2-325C-438B-BB7D-B524F66A875EQ24198155-B8744B73-AC6B-46BB-AD34-8185746E8D9AQ24243912-F1B30308-F718-4B02-84C3-0AC9918D5A10Q24246515-F4E27AC0-88A8-47CE-BE6A-A7CB880C7420Q28073426-EEEFCCAF-FE8E-4AAA-929A-A963E613C3E0Q28487597-B69070AE-012C-47F4-B0D8-7695699302E0Q33409652-6CD116AF-D8EC-46A3-8F1B-77709596953EQ33929849-E1A02F75-9B41-4A96-9B43-AEBE5C56EA25Q34024866-5281F90F-9E21-48A6-81AC-4A5C39BE1855Q34108585-5A619853-E861-4C07-A590-F05C1D76DCDEQ34182814-A2348A0E-28B9-4466-A199-19F8F8B05BCFQ34247073-37031940-4131-49F4-9C89-36B26ABE8754Q34763371-8194480C-D4E2-40A9-91AB-5AFD3BDC5974Q34806920-4732A763-F5CD-4E79-8F93-551182D16E3FQ34960317-88C3A008-7A1A-4D07-B576-F5450397640CQ35012968-7604E177-42CC-4680-8B15-47030098597FQ35168703-264ED4C1-1675-4DA2-8444-C0BD322DD6F6Q36071267-BC1AC7C4-B7AF-4ECD-9317-88CF1E9282E5Q36140647-AEC8B2E9-1AD5-4B91-BC3E-A960EB903B52Q36248701-845BE9CF-D1BD-4360-A004-AB458CE75B91Q36489697-E218E8BF-8FE0-424F-B3DD-0B44E28F08DAQ36868273-96324A90-BB7C-4796-B1DB-471C1E2DF554Q36920328-FE7C4911-1638-47A3-822D-D47ADCC32E7BQ37065265-073D8DA8-4CFC-48B5-ADB3-7756EF874294Q37071358-4226F7D8-248F-4B0B-9FED-521C557572E1Q37178176-9BC6BF18-36E9-4D47-AEB4-62F4022A1E40Q37508725-DC1C2287-0CFB-43B6-9D2F-A7F774401876Q37562147-4C557D3B-E77B-4657-B263-763E5659627FQ37598729-7D6746E9-EDCB-4120-B67E-9CDE7BA50CF3Q37904672-55A4C5B4-899E-4A41-96E7-91D25A970296Q38106032-44425564-BE28-4A17-8BCA-F60839F5A6F4Q38154347-CC8F80D6-F1A6-4A06-ACB1-90D89C3A8542Q38203377-6F754F1A-B6BF-4282-B073-7A6150E4A7EAQ38233071-18A5ADC8-9E0A-4860-A1E6-3FC4C7769AB0Q38556616-871F414B-80ED-40D9-8DBE-F3113000D5B2Q38681635-84206D4C-14D4-49FC-9A25-627A391DED12Q38718391-F7089F2B-CBF4-43FA-928A-18FEA61C80E3Q38758771-D9D0DEE4-1648-4E11-8CF4-A79BC53BE5FC
P2860
AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@ast
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@en
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@nl
type
label
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@ast
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@en
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@nl
prefLabel
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@ast
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@en
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@nl
P356
P1476
AmBisome: liposomal formulatio ...... n and pre-clinical experience.
@en
P2093
Jill Adler-Moore
Richard T Proffitt
P356
10.1093/JAC/49.SUPPL_1.21
P407
P478
49 Suppl 1
P577
2002-02-01T00:00:00Z